<rt id="cseoq"><small id="cseoq"></small></rt><acronym id="cseoq"><center id="cseoq"></center></acronym>
首頁 >科研隊伍 >研究員

研究員

姓名 莊光磊 性別
專家類別 上海市青年科技啟明星
學歷 博士 職稱 研究員
聯系電話 021-34208662 電子郵箱 zhuanglab@163.com
通訊地址 上海交通大學閔行校區文選醫學樓426室
個人簡介

2004年畢業于北京大學獲生物科學本科學位;2010年獲美國范德比爾特大學癌癥生物學博士學位;2010年至2014年在美國羅氏/基因泰克制藥公司從事博士后研究?,F擔任癌基因及相關基因國家重點實驗室課題組長,上海交通大學醫學院附屬仁濟醫院婦產科研究員,主要研究方向為腫瘤分子診斷和靶向治療。承擔美國國防部博士研究基金、國家自然科學基金面上項目,入選2016年上海市青年科技啟明星,2016年上海交通大學醫學院“雙百人”計劃,擔任中國生理學會基質生物學委員會委員,Plos Genetics, Genome Research, BMC Cancer等雜志審稿專家,在國際期刊已發表論文30余篇,參與編寫英文專著一部。

研究方向

腫瘤高通量測序與克隆進化

肺癌卵巢癌的分子機制和靶向治療


科研論文

代表性論文

1.      Zhang S., Zhang M., Jing Y., Yin X., Ma P., Zhang Z., Wang X., Di W., Zhuang G. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 

2.      Jing Y., Zhang R., Ma P., Cai M.C., Zhuang G.*, Chen H*. Prevalence and clonality of synchronous primary carcinomas in the bladder and prostate. J Pathol. (co-corresponding author)

3.      Ma P., Fu Y., Cai M.C., Yan Y., Jing Y., Zhang S., Chen M., Wu J., Shen Y., Zhu L., Chen H.Z., Gao W.Q., Wang M., Gu Z., Bivona T.G., Zhao X.*, Zhuang G*. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nat Commun. (co-corresponding author)

4.      Yin X., Jing Y., Cai M.C., Ma P., Zhang Y., Xu C., Zhang M., Di W.*, Zhuang G*. Clonality, heterogeneity and evolution of synchronous bilateral ovarian cancer. Cancer Res. (co-corresponding author)

5.      Zhang Z., Peng H., Wang X., Yin X., Ma P., Jing Y., Cai M.C., Liu J., Zhang M., Zhang S., Shi K., Gao W.Q., Di W., Zhuang G. Preclinical efficacy and molecular mechanism of targeting CDK7-dependent transcriptional addiction in ovarian cancer. Mol Cancer Ther.

6.      Zhang M.*, Zhuang G.*, Sun X., Shen Y., Wang W., Li Q., Di W. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer. Diagn Pathol. (co-first author)

7.      Yin X., Wang X., Shen B., Jing Y., Li Q., Cai M.C., Gu Z., Yang Q., Zhang Z., Liu J., Li H., Di W.*, Zhuang G. * A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis. Sci Rep. (co-corresponding author)

8.      Ma P., Fu Y., Chen M., Jing Y., Wu J., Li K., Shen Y., Gao J.X., Wang M., Zhao X.*, Zhuang G. * Adaptive and acquired resistance to EGFR inhibitors converge on the MAPK pathway. Theranostics. (co-corresponding author)

9.      Zhang Z., Ma P., Jing Y., Yan Y., Cai M.C., Zhang M., Zhang S., Peng H., Ji Z.L., Di W., Gu Z., Gao W.Q., Zhuang G. BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1. Theranostics.

10.   Jing Y., Zhang Z., Ma P., An S., Shen Y., Zhu L., Zhuang G. Concomitant BET and MAPK blockade for effective treatment of ovarian cancer. Oncotarget.

11.   Zhang S., Jing Y., Zhang M., Zhang Z., Ma P., Peng H., Shi K., Gao W.Q.*, Zhuang G.* Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. Sci Rep. (co-corresponding author)

12.   Zhang M., Zhuang G., Sun X., Shen Y., Zhao A., Di W. Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics. J Ovarian Res.

13.   Zhuang G., Ferrara N. The VEGF Receptor Family. Receptor Tyrosine Kinases: Family and Subfamilies (Book chapter).

14.   Zhu H.H.*, Zhuang G.*, Gao W.Q. A candidate gastric stem/progenitor cell marker revealed by genome wide analysis. J Pathol. (co-first author)

15.   Zhang Z., Zhang S., Ma P., Jing Y., Peng H., Gao W.Q.*, Zhuang G.* Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit. Carcinogenesis. (co-corresponding author)

16.   Sun Y., Daemen A., Hatzivassiliou G., Arnott D., Wilson C., Zhuang G., Gao M., Liu P., Boudreau A., Johnson L., Settleman J. Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. Cancer Metab.

17.   Li X., Liu Y., Chen W., Fang Y., Xu H., Zhu H., Chu M., Li W., Zhuang G.*, Gao W.Q.* TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer. Oncotarget. (co-corresponding author)

18.   Lee H.J., Zhuang G., Cao Y., Du P., Kim H.J., Settleman J. Drug resistance via feedback activation of stat3 in oncogene-addicted cancer cells. Cancer Cell.

19.   18.? Chung A.S., Wu X?., Zhuang G., Ngu H., Kasman I., Zhang J., Vernes J.M., Jiang Z., Meng Y.G., Peale F.V., Ouyang W., Ferrara N. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nature Medicine.

20.   Sampath D., Oeh J., Wyatt S.K., Cao T.C., Koeppen H., Eastham-Anderson J., Robilard L., Ho C.C., Ross J., Zhuang G., Reslan H.B., Vitorino P., Barck K.H., Ungersma S.E., Vernes J.M., Caunt M., Van Bruggen N., Ye W., Vijapurkar U., Meng Y.J., Ferrara N., Friedman L.S., Carano R.A. Multi-modal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an anti-vascular response. Neoplasia.

21.   Brauer M.J.*, Zhuang G.*, Schmidt M.*, Yao J., Wu X., Kaminker J.S., Jurinka S.S., Kolumam G., Chung A.S., Jubb A., Modrusan Z., Ozawa T., James C.D., Phillips H., Haley B., Tam R.N., Clermont A.C., Cheng J.H., Yang S.X., Swain S.M., Chen D., Scherer S.J., Koeppen H., Yeh R.F., Yue P., Stephan J.P., Hedge P., Ferrara N., Singh M., Bais C. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clinical Cancer Research. (co-first author)

22.   Zhuang G.*, Yu K.*, Jiang Z., Chung A.S., Yao J., Ha C., Toy K., Soriano R., Haley B., Blackwood E., Sampath D., Bais C., Lill J.R., Ferrara N. Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Science Signaling. (co-first author)

23.   Phan V.T., Wu X., Cheng J.H., Sheng R.X., Chung A.S., Zhuang G., Tran C., Song Q., Kowanetz M., Sambrone A., Tan M., Meng Y.G., Peale F.V., Junttila M.R., Ferrara N. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A. 

24.   Zhuang G.*, Song W.*, Amato K., Hwang Y., Lee K., Boothby M., Ye F., Guo Y., Shyr Y., Lin L., Carbone D.P., Brantley-Sieders D.M., Chen J. Effects of cancer-associated EPHA3 mutations on lung cancer. Journal of the National Cancer Institute. (co-first author)

25.   Zhuang G., Wu X., Jiang Z., Kasman I., Yao J., Qu X., Guan Y., Oeh J., Modrusan Z., Bais C., Sampath D., Ferrara N. Tumor-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. The EMBO Journal.

26.   Chung A.S., Kowanetz M., Wu X., Zhuang G., Ngu H., Finkle D., Komuves L., Peale F., Ferrara N. Differential drug-class specific metastatic effects following treatment with a panel of angiogenesis inhibitors. The Journal of Pathology.

27.   Qu X., Zhuang G., Yu L., Meng G., Ferrara N. Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. The Journal of Biological Chemistry.

28.   Yao J., Wu X., Zhuang G., Kasman I.M., Vogt T., Phan V., Shibuya M., Ferrara N., Bais C. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A.

29.   Zhuang G., Brantley-Sieders D.M., Vaught D., Yu J., Xie L., Wells S., Jackson D., Muraoka-cook R.S., Arteaga C.L., Chen J. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Research.

30.   Brantley-Sieders D.M., Zhuang G., Vaught D., Freeman T., Hwang Y., Hicks D., Chen J. Host-deficiency in Vav 2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo. Molecular Cancer Research.

31.   Chen J., Zhuang G., Frieden L., Debinski W. Eph receptors and Ephrins in Cancer: Common Themes and Controversies. Cancer Research.

32.   Fang W.B., Ireton R.C., Zhuang G., Takahashi T., Reynolds A., Chen J. Overexpression of EphA2 receptor destabilizes adherens junction via a RhoA-dependent mechanism. Journal of Cell Science.

33.   Brantley-Sieders D.M.*, Zhuang G.*, Hicks D., Fang W.B., Hwang Y., Cates J.M., Coffman K., Jackson D., Bruckheimer E., Muraoka-Cook R.S., Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. The Journal of Clinical Investigation. (co-first author)

34.    Zhuang G., Hunter S., Hwang Y., Chen J. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. The Journal of Biological Chemistry.

35.   Hunter S.G., Zhuang G., Brantley-Sieders D., Swat W., Cowan C.W., Chen J. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Molecular and Cellular Biology.

36.   Brantley-Sieders D.M., Fang W.B., Hicks D.J., Zhuang G., Shyr Y., Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. The FASEB Journal


科研項目

1. 國家自然科學基金面上項目, 2017/01-2020/12

2. 上海青年科技啟明星計劃,2016/01-2018/12

3. 國家自然科學基金面上項目,2015/01-2018/12

4. 美國國防部乳腺癌項目博士研究基金,2008/01-2010/12 


獲得專利
實驗室成員

景瑩 (助理研究員)

張振峰 (助理研究員)

劉錦 (助理研究員)

蔡梅春 (助理研究員)

馬鵬飛 (助理研究員)

張生哲 (博士研究生)

師凱旋 (博士研究生)

沈佩燁 (博士研究生)

逯海嬌 (博士研究生)

彭慧昕 (博士研究生)

賈晨強 (博士研究生)


ICP備案號:滬ICP備15036656號-1 版權所有:上海市腫瘤研究所
日韩欧美中文字慕在线-更新最快的高清无码中文字幕视频国产影院